AMGN:NASDAQ
Amgen Inc
$418.13
arrow_upward
+0.85%(+3.52) 1D
$418.13
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 28, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMGN...
Open
$411.52
High
$419.02
Low
$410.96
Mkt. cap
226.05B
Avg. vol.
2.83M
Volume
0.00
Dividend
2.41%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
25.97
52-wk high
$447.01
52-wk low
$270.67
EPS
$16.10
Beta
0.43
Shares outstanding
540.63M
No. of employees
32K
Open
$411.52
High
$419.02
Low
$410.96
Mkt. cap
226.05B
Avg. vol.
2.83M
Volume
0.00
Dividend
2.41%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
25.97
52-wk high
$447.01
52-wk low
$270.67
EPS
$16.10
Beta
0.43
Shares outstanding
540.63M
No. of employees
32K
News stories
From web sources and news partners
Yahoo Finance
·
4 hours ago
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?
Stock Traders Daily
·
5 hours ago
Understanding the Setup: (AMGN) and Scalable Risk
Yahoo Finance
·
5 hours ago
Amgen (AMGN), What Is Behind The Fresh Attention?
AD HOC NEWS
·
12 hours ago
Amgen stock last trades at USD 418.60 on September 28, 2026
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31.5K
FoundedApr 8, 1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com